Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women

INTRODUCTION: In addition to their antihyperglycemic action, sodium-glucose cotransporter-2 (SGLT2) inhibitors are used in patients with type 2 diabetes due to their cardioprotective effects. Meta-analyses of large clinical trials have reported mixed results when examining sex differences in their c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pruett, Jacob E, Lirette, Seth T, Romero, Damian G, Yanes Cardozo, Licy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795477/
https://www.ncbi.nlm.nih.gov/pubmed/36601021
http://dx.doi.org/10.1210/jendso/bvac191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795477/
https://www.ncbi.nlm.nih.gov/pubmed/36601021
http://dx.doi.org/10.1210/jendso/bvac191

Ejemplares similares